Lineage Cell Therapeutics in the first quarter: science advanced, cash still sets the pace
Lineage opened 2026 with more clinical and manufacturing progress across several cell-therapy programs, but the quarter also showed that the lead asset is still controlled by Roche and the company is funding time until external milestones arrive. The real issue is not the loss itself, but the gap between the broad scientific option and the value actually accessible to shareholders after cash burn, dilution, and downstream obligations.
Lineage Cell Therapeutics did not report a quarter that settles the company story, but it did report a quarter that clarifies the proof test. On the science side, OpRegen gained support from longer follow-up data, OPC1 advanced in a spinal cord injury study, ReSonance completed early manufacturing work, and two newer initiatives began to show up in the development budget. On the economics side, this is still a biotech company selling time: first-quarter revenue was only $1.7 million, operating cash flow was negative $8.1 million, and new capital came mainly from warrant exercises rather than from the business itself. The active bottleneck is not immediate liquidity, because the company ended March with $53.4 million in cash and marketable securities, but the quality of the path from trial progress to cash. Roche controls the OpRegen path, part of future receipts will flow to IIA and Hadasit layers, and the capital market remains an active funding source. The next few quarters therefore need to prove more than additional scientific progress. They need clearer movement toward binding milestones, less dilutive funding, and progress that changes the probability of future revenue rather than only expanding the list of programs.
A Cell Therapy Platform That Measures Time, Not Revenue
The company develops cell replacement therapies for diseases in which lost or damaged cellular function is part of the disease itself. Its economic engine is not ordinary product sales. It is movement between proof stages: trial, partner, milestone, future royalty, or expansion of the platform into another program. That makes it a scientific growth company with a funding bottleneck, not a revenue company.
The business map is fairly straightforward. OpRegen, an RPE cell therapy for geographic atrophy secondary to dry age-related macular degeneration, is the most advanced asset and is being developed through Roche and Genentech. OPC1 is a clinical-stage spinal cord injury program. ReSonance, an auditory neuron progenitor cell therapy, is in preclinical development under a collaboration with William Demant Invest. COR1 and ILT1 are newer moves around corneal disease and broader large-scale cell manufacturing. The common base is AlloSCOPE, the company's manufacturing platform, which is meant to support consistent, scalable, off-the-shelf cell production.
The easy mistake is to count programs and treat the breadth itself as value. The programs are not economically equal. OpRegen is closer to potential commercialization, but much of the control and future value sits with Roche. The internal programs provide broader optionality, but they consume time and cash before they can carry the company. In the first quarter of 2026, this became less of a pure science question and more of a capital-allocation question: how much cash should the company spend to widen the platform before the lead asset delivers another milestone.
The Quarter Advanced Several Assets, But OpRegen Still Holds Most of the Option Value
One positive development stands above the rest. In May 2026, Roche and Genentech presented 36-month follow-up data from the Phase 1/2a OpRegen study. Among patients who received extensive coverage of their atrophy area with OpRegen cells, the five patients completing three-year follow-up showed a mean best-corrected visual acuity change of +9.0 letters, compared with +7.4 letters at 24 months. This matters because it extends the durability window of the clinical signal rather than merely repeating a short-term endpoint. Still, the right framing is measured. The study was open-label, single-arm, and included 24 patients across four cohorts. The commercial read will change only if GAlette, the Phase 2a study enrolling up to 60 patients at 17 sites in the U.S. and Israel, leads to a broader and more binding development decision.
The other programs also moved forward, but from earlier stages. In OPC1, the second chronic spinal cord injury participant with neurologically complete injury was treated in March 2026 in the DOSED study, using a novel one-time delivery system. ReSonance completed three engineering manufacturing runs and is preparing for internal technology transfer to the cGMP team. COR1 was launched as a preclinical corneal endothelial cell program, and ILT1 met a first milestone by demonstrating a fully suspension-based process for generating undifferentiated pluripotent cells at 0.5-liter scale. These are not revenue events, but they explain why development spending rose.
This mix tells the story better than the top line. OpRegen and OPC1 together took about 61% of R&D spending, ReSonance took 22%, and COR1 plus ILT1 already accounted for roughly 12%. In other words, the company is not merely waiting for Roche. It is also funding a portfolio of internal programs, some still at a very early stage. That can increase platform value if another program attracts a partner, but it also raises the need for a stronger cash base while revenue remains modest.
The Big Roche Number Is Not All Accessible Value
The Roche agreement is the main reason OpRegen looks different from the rest of the pipeline. Roche paid $50 million upfront in January 2022 and another $5 million milestone in December 2025. The company remains eligible for up to $615 million in additional milestones, plus tiered double-digit royalties on future net sales in major markets. But that headline number is not the same as value fully accessible to common shareholders.
First, Roche is responsible for further clinical development and commercialization, so the company does not fully control the pace. Second, the OpRegen path was built on Israeli intellectual property and support that create additional payment layers. On the $5 million milestone received in December 2025, the company funded a $1.2 million payment to the IIA and a $1.1 million payment to Hadasit in January 2026. In other words, almost half of the first post-upfront milestone left the company structure before investors even consider ongoing operating needs.
| OpRegen Value Layer | Current Position | Why It Matters |
|---|---|---|
| Roche | Up to $615 million of additional milestones and tiered royalties | The economic option is large, but the pace is not controlled only by the company |
| IIA | About 24.1% of future Roche payments up to an aggregate cap of about $96.7 million | Part of the upside flows to the earlier public-funding layer |
| Hadasit | Up to 21.5% of milestones and up to 50% of royalties, subject to a 5% net-sales cap | Accessible value is lower than the gross collaboration number |
| Shareholders | Receive what remains after partners, obligations, and cash burn | The test is not only scientific success, but how much cash remains in the company |
This does not make Roche less important. On the contrary, a partner like Roche lowers a meaningful part of the development and commercialization risk. But it changes the analysis. The relevant question is not only “up to $615 million.” It is how much of that path turns into actual receipts, when those receipts arrive, and how much remains after downstream obligations.
The All-In Cash Picture Sets the Waiting Pace
First-quarter revenue rose 15% to $1.7 million, mostly because collaboration revenue increased to $1.6 million. The positive read is that the WDI collaboration is starting to appear in revenue. The less comfortable read is that the entire revenue base is still small against $9.3 million of operating expenses. Research and development expense rose 36% to $4.2 million, while general and administrative expense rose 5% to $5.1 million. Operating loss widened to $7.6 million before non-cash items such as the change in fair value of warrant liabilities.
The all-in cash picture matters more here than net loss. In the first quarter, the company used $8.1 million in operating cash, compared with $4.9 million in the prior-year quarter. After net investing activity in securities and equipment, and against $5.6 million of financing inflow mainly from warrant exercises, cash and marketable securities stood at $53.4 million at the end of March. That is not immediate liquidity stress, but it is not a picture that lets investors ignore dilution. Common shares rose from 243.1 million at the end of 2025 to 249.3 million at the end of March 2026, mainly through the exercise of 5.9 million warrants.
Beyond that, 35.2 million warrants remained outstanding at a weighted average exercise price of $0.91, and the company notes that it may receive up to an additional $30.2 million if those warrants are exercised for cash. That is an option, not a guaranteed funding source. The company also has an ATM program that allows up to $60 million of additional share sales, unused during the quarter. Without a new milestone, the market will continue to measure the company by its cash balance, burn rate, and Roche's ability to move OpRegen toward a trial that provides a more credible commercialization read.
Conclusions
The first quarter of 2026 improved the scientific side of the company, but it did not solve the economic side. The new OpRegen data support continued interest in the asset, and the platform expansion through ReSonance, COR1, and ILT1 shows that the company is not dependent on a single program. Still, negative operating cash flow of $8.1 million, development spending that is rising faster than revenue, and reliance on warrant exercises or potential share sales keep the company in a funding proof year. The strength is that the cash balance supports planned operations for at least 12 months from the filing date. The weakness is that the longer path still needs a Roche milestone, another partnership, or sustained access to the capital market.
What can change the market read over the next few quarters is not another expansion of the program list, but progress that reduces economic uncertainty. A Roche decision to move OpRegen into a broader controlled trial, ReSonance moving into a more binding clinical or commercial framework, or proof that ILT1 can scale beyond 0.5 liters without a cost step-up would read very differently from continued cash burn on early development. Conversely, an OpRegen delay, use of the ATM before a meaningful milestone, or disruption to the Jerusalem manufacturing operation would weigh on the thesis even if the scientific data remain encouraging. The company still holds a broad biotech option, but this quarter made clearer that the option needs to become cash before dilution becomes too large a part of the story.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.